nach oben

Clinical and Translational Oncology

Erschienen in:

05.07.2023 | RESEARCH ARTICLE

The role of the mitochondrial ribosomal protein family in detecting hepatocellular carcinoma and predicting prognosis, immune features, and drug sensitivity

verfasst von: Jin-Wei Zhao, Wei-Yi Zhao, Xin-Hua Cui, Lin Xing, Jia-Cheng Shi, Lu Yu

Erschienen in: Clinical and Translational Oncology | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

Hepatocellular carcinoma (HCC) is one of the most common types of malignant tumors, with a slow onset, rapid progression, and frequent recurrence. Previous research has implicated mitochondrial ribosomal genes in the development, metastasis, and prognosis of various cancers. However, further research is necessary to establish a link between mitochondrial ribosomal protein (MRP) family expression and HCC diagnosis, prognosis, ferroptosis-related gene (FRG) expression, m6A modification-related gene expression, tumor immunity, and drug sensitivity.

Methods

Bioinformatics resources were used to analyze data from patients with HCC retrieved from the TCGA, ICGC, and GTEx databases (GEPIA, UALCAN, Xiantao tool, cBioPortal, STRING, Cytoscape, TISIDB, and GSCALite).

Results

Among the 82 MRP family members, 14 MRP genes (MRPS21, MRPS23, MRPL9, DAP3, MRPL13, MRPL17, MRPL24, MRPL55, MRPL16, MRPL14, MRPS17, MRPL47, MRPL21, and MRPL15) were significantly upregulated differentially expressed genes (DEGs) in HCC tumor samples in comparison to normal samples. Receiver-operating characteristic curve analysis indicated that all 14 DEGs show good diagnostic performance. Furthermore, TCGA analysis revealed that the mRNA expression of 39 MRPs was associated with overall survival (OS) in HCC. HCC was divided into two molecular subtypes (C1 and C2) with distinct prognoses using clustering analysis. The clusters showed different FRG expression and m6A methylation profiles and immune features, and prognostic models showed that the model integrating 5 MRP genes (MRPS15, MRPL3, MRPL9, MRPL36, and MRPL37) and 2 FRGs (SLC1A5 and SLC5A11) attained a greater clinical net benefit than three other prognostic models. Finally, analysis of the CTRP and GDSC databases revealed several potential drugs that could target prognostic MRP genes.

Conclusion

We identified 14 MRP genes as HCC diagnostic markers. We investigated FRG and m6A modification-related gene expression profiles and immune features in patients with HCC, and developed and validated a model incorporating MRP and FRG expression that accurately and reliably predicts HCC prognosis and may predict disease progression and treatment response.

Kao JH, Chen DS. Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia. Liver Int. 2005;25:696–703.CrossRefPubMed

McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of Hepatocellular Carcinoma. Hepatology. 2021;73(Suppl 1):4–13. https://doi.org/10.1002/hep.31288.CrossRefPubMed

Lohitesh K, Chowdhury R, Mukherjee S. Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight. Cancer Cell Int. 2018;18:44. https://doi.org/10.1186/s12935-018-0538-7. (PMID:29568237).CrossRefPubMedPubMedCentral

De Silva D, Tu YT, Amunts A, Fontanesi F, Barrientos A. Mitochondrial ribosome assembly in health and disease. Cell Cycle. 2015;14(14):2226–50. https://doi.org/10.1080/15384101.2015.1053672.CrossRefPubMedPubMedCentral

Mai N, Chrzanowska-Lightowlers ZM, Te Lightowlers RN. process of mammalian mitochondrial protein synthesis. Cell Tissue Res. 2017;367:5–20. https://doi.org/10.1007/s00441-016-2456-0.CrossRefPubMed

Wazir U, Orakzai MM, Khanzada ZS, Jiang WG, Sharma AK, Kasem A, et al. The role of death-associated protein 3 in apoptosis, anoikis and human cancer. Cancer Cell Int. 2015;15:39. https://doi.org/10.1186/s12935-015-0187-z.CrossRefPubMedPubMedCentral

Conde JA, Claunch CJ, Romo HE, Benito-Martin A, Ballestero RP, Gonzalez-Garcia M. Identifification of a Motif in BMRP required for interaction With Bcl-2 by site-directed mutagenesis studies. J Cell Biochem. 2012;113(11):3498–508. https://doi.org/10.1002/jcb.24226.CrossRefPubMed

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. https://doi.org/10.1016/j.cell.2011.02.013.CrossRefPubMed

Lee Y-K, Lim JJ, Jeoun U-W, Min S, Lee E-B, Kwon SM, et al. Lactate-mediated mitoribosomal defects impair mitochondrial oxidative phosphorylation and promote hepatoma cell invasiveness. J Biol Chem. 2017;292:20208–17.CrossRefPubMedPubMedCentral

10.

Pu M, Wang J, Huang Q, Zhao G, Xia C, Shang R, et al. High MRPS23 expression contributes to hepatocellular carcinoma proliferation and indicates poor survival outcomes. Tumour Biol. 2017. https://doi.org/10.1177/1010428317709127.CrossRefPubMed

11.

Zhou C, Chen Z, Peng C, Chen C, Li H. Long Noncoding RNA TRIM52-AS1 sponges miR-514a-5p to facilitate hepatocellular carcinoma progression through increasing MRPS18A. Cancer Biother Radiopharm. 2021;36(2):211–9.PubMed

12.

Zhuang R, Lu D, Zhuo J, Zhang X, Wang K, Wei X, et al. CR6-interacting factor 1 inhibits invasiveness by suppressing TGF-β-mediated epithelial-mesenchymal transition in hepatocellular carcinoma. Oncotarget. 2017;8:94759–68.CrossRefPubMedPubMedCentral

13.

Manz DH, Blanchette NL, Paul BT, Torti FM, Torti SV. Iron and cancer: recent insights. Ann NY Acad Sci. 2016;1368:149–61. https://doi.org/10.1111/nyas.13008.CrossRefPubMed

14.

Li C, Zhang Y, Liu J, Kang R, Klionsky DJ, Tang D. Mitochondrial DNA stress triggers autophagy-dependent ferroptotic death. Autophagy. 2021;17:948–60. https://doi.org/10.1080/15548627.2020.1739447.CrossRefPubMed

15.

Tang B, Zhu J, Li J, Fan K, Gao Y, Cheng S, et al. The ferroptosis and iron-metabolism signature robustly predicts clinical diagnosis, prognosis and immune microenvironment for hepatocellular carcinoma. Cell Commun Signal. 2020;18(1):174. https://doi.org/10.1186/s12964-020-00663-1.CrossRefPubMedPubMedCentral

16.

Yu J, Wang J-Q. Research mechanisms of and pharmaceutical treatments for ferroptosis in liver diseases. Biochimie. 2021;180:149–57. https://doi.org/10.1016/j.biochi.2020.11.002.CrossRefPubMed

17.

Lan Q, Liu PY, Haase J, Bell JL, Hüttelmaier S, Liu T. The critical role of RNA m6A methylation in cancer. Cancer Res. 2019;79(7):1285–92.CrossRefPubMed

18.

He L, Li H, Wu A, Peng Y, Shu G, Yin G. Functions of N6-methyladenosine and its role in cancer. Mol Cancer. 2019;18(1):176.CrossRefPubMedPubMedCentral

19.

Chen XY, Zhang J, Zhu JS. The role of m6A RNA methylation in human cancer. Mol Cancer. 2019;18(1):103.CrossRefPubMedPubMedCentral

20.

Ye J, Wang Z, Chen X, Jiang X, Dong Z, Hu S, Li W, et al. YTHDF1-enhanced iron metabolism depends on TFRC m(6)A methylation. Theranostics. 2020;10(26):12072–89.CrossRefPubMedPubMedCentral

21.

Song Z, Jia G, Ma P, Cang S. Exosomal miR-4443 promotes cisplatin resistance in non-small cell lung carcinoma by regulating FSP1 m6A modifcation-mediated ferroptosis. Life Sci. 2021;276: 119399.CrossRefPubMed

22.

The Cancer Genome Atlas Network. Genomic classifification of cutaneous melanoma. Cell. 2015;161(7):1681–96. https://doi.org/10.1016/j.cell.2015.05.044.CrossRefPubMedCentral

23.

Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profling and interactive analysis. Nucl Acids Res. 2019;47:W556–60. https://doi.org/10.1093/nar/gkz430.CrossRefPubMedPubMedCentral

24.

Chandrashekar DS, Karthikeyan SK, Korla PK, Patel H, Shovon AR, Athar M, et al. UALCAN: an update to the integrated cancer data analysis platform. Neoplasia. 2022;25:18–27. https://doi.org/10.1016/j.neo.2022.01.001.CrossRefPubMedPubMedCentral

25.

Yan Y, Li J, Ye M, Li Z, Li S. Tropomyosin is potential markers for the diagnosis and prognosis of bladder cancer. Dis Markers. 2022;2022:6936262. https://doi.org/10.1155/2022/6936262.CrossRefPubMedPubMedCentral

26.

Chen F, Chandrashekar D, Varambally S, Creighton C. Pan-cancer molecular subtypes revealed by mass-spectrometry-based proteomic characterization of more than 500 human cancers. Nat Commun. 2019;10:5679. https://doi.org/10.1038/s41467-019-13528-0.CrossRefPubMedPubMedCentral

27.

Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profles using the cBioPortal. Sci Signal. 2013;6:269. https://doi.org/10.1126/scisignal.2004088.CrossRef

28.

Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, et al. The STRING database in 2021: customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucl Acids Res. 2021;49:D605–12. https://doi.org/10.1093/nar/gkaa1074.CrossRefPubMed

29.

Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a sofware environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498–504. https://doi.org/10.1101/gr.1239303.CrossRefPubMedPubMedCentral

30.

Zhang Z, Lin E, Zhuang H, Xie L, Feng X, Liu J, et al. Construction of a novel gene-based model for prognosis prediction of clear cell renal cell carcinoma. Cancer Cell Int. 2020;20:27. https://doi.org/10.1186/s12935-020-1113-6. (eCollection 2020).CrossRefPubMedPubMedCentral

31.

Liu CJ, Hu FF, Xia MX, Han L, Zhang Q, Guo AY. GSCALite: a web server for gene set cancer analysis. Bioinformatics. 2018;34(21):3771–2. https://doi.org/10.1093/bioinformatics/bty411.CrossRefPubMed

32.

Liu Z, Zhao Q, Zuo ZX, Yuan SQ, Yu K, Zhang Q, et al. Systematic analysis of the aberrances and functional implications of ferroptosis in cancer. iScience. 2020;23(7):101302. https://doi.org/10.1016/j.isci.2020.101302. (10.1016/j.isci.2020.101302).CrossRefPubMedPubMedCentral

33.

Li Y, Xiao J, Bai J, Tian Y, Qu Y, Chen X, et al. Molecular characterization and clinical relevance of m6A regulators across 33 cancer types. Mol Cancer. 2019;18(1):137. https://doi.org/10.1186/s12943-019-1066-3.CrossRefPubMedPubMedCentral

34.

Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509–14. https://doi.org/10.1093/nar/gkaa407.CrossRefPubMedPubMedCentral

35.

Ravi R, Noonan KA, Pham V, Bedi R, Zhavoronkov A, Ozerov IV, et al. Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy. Nat Commun. 2018;9(1):741. https://doi.org/10.1038/s41467-017-02696-6.CrossRefPubMedPubMedCentral

36.

Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550–8. https://doi.org/10.1038/s41591-018-0136-1.CrossRefPubMedPubMedCentral

37.

Alba AC, Agoritsas T, Walsh M, Hanna S, Iorio A, Devereaux PJ, et al. Discrimination and calibration of clinical prediction models: users’ guides to the medical literature. JAMA. 2017;318(14):1377–84. https://doi.org/10.1001/jama.2017.12126.CrossRefPubMed

38.

Chang CW, Wei Z, Durell SR, Ma L, Forgues M, Wang XW. A compendium of co-regulated mitoribosomal proteins in pan-cancer uncovers collateral defective events in tumor malignancy. iScience. 2022;25(10):105244. https://doi.org/10.1016/j.isci.2022.105244. (eCollection 2022 Oct 21).CrossRefPubMedPubMedCentral

39.

Lin X, Guo L, Lin X, Wang Y, Zhang G. Expression and prognosis analysis of mitochondrial ribosomal protein family in breast cancer. Sci Rep. 2022;12(1):10658. https://doi.org/10.1038/s41598-022-14724-7.CrossRefPubMedPubMedCentral

40.

Li XQ, Guo YY, De W. DNA Methylation and microRNAs in Cancer. World J Gastroenterol. 2012;18(9):882–8. https://doi.org/10.3748/wjg.v18.i9.882.CrossRefPubMedPubMedCentral

41.

Timp W, Feinberg AP. Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat Rev Cancer. 2013;13:497–510.CrossRefPubMedPubMedCentral

42.

Wei Z, Jia J, Heng G, Xu H, Shan J, Wang G, et al. Sirtuin-1/Mitochondrial Ribosomal protein S5 axis enhances the metabolic flexibility of liver cancer stem cells. Hepatology. 2019;70(4):1197–213. https://doi.org/10.1002/hep.30622.CrossRefPubMed

43.

Kim SJ, Kwon MC, Ryu MJ, Chung HK, Tadi S, Kim YK, et al. CRIF1 is essential for the synthesis and insertion of oxidative phosphorylation polypeptides in the mammalian mitochondrial membrane. Cell Metab. 2012;16:274–83.CrossRefPubMed

44.

Chang H, Li J, Qu K, Wan Y, Liu S, Zheng W, et al. CRIF1 overexpression facilitates tumor growth and metastasis through inducing ROS/NFkappaB pathway in hepatocellular carcinoma. Cell Death Dis. 2020;11:332.CrossRefPubMedPubMedCentral

45.

Liu L, He J, Sun G, Huang N, Bian Z, Xu C, et al. The N6-methyladenosine modification enhances ferroptosis resistance through inhibiting SLC7A11 mRNA deadenylation in hepatoblastoma. Clin Transl Med. 2022;12(5):e778. https://doi.org/10.1002/ctm2.778.CrossRefPubMedPubMedCentral

46.

Han D, Liu J, Chen C, Dong L, Liu Y, Chang R, et al. Anti-tumour immunity controlled through mRNA m6A methylation and YTHDF1 in dendritic cells. Nature. 2019;566:270–4.CrossRefPubMedPubMedCentral

47.

Wang W, Green M, Choi JE, Gijón M, Kennedy PD, Johnson JK, et al. CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569:270–4. https://doi.org/10.1038/s41586-019-1170-y.CrossRefPubMedPubMedCentral

48.

Liu J, Lu J, Li W. A comprehensive prognostic and immunological analysis of a new three-gene signature in hepatocellular carcinoma. Stem Cells Int. 2021;2021:5546032. https://doi.org/10.1155/2021/5546032.CrossRefPubMedPubMedCentral

49.

Li M, Liu Z, Wang J, Liu H, Gong H, Li S, et al. Systematic analysis identifies a specifific RNA-binding protein-related gene model for prognostication and risk-adjustment in HBV-related hepatocellular carcinoma. Front Genet. 2021;12:707305. https://doi.org/10.3389/fgene.2021.707305.CrossRefPubMedPubMedCentral

50.

Titel: The role of the mitochondrial ribosomal protein family in detecting hepatocellular carcinoma and predicting prognosis, immune features, and drug sensitivity
verfasst von: Jin-Wei Zhao
Wei-Yi Zhao
Xin-Hua Cui
Lin Xing
Jia-Cheng Shi
Lu Yu
Publikationsdatum: 05.07.2023
Verlag: Springer International Publishing
Erschienen in: Clinical and Translational Oncology / Ausgabe 2/2024
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-023-03269-4

Springer Medizin

The role of the mitochondrial ribosomal protein family in detecting hepatocellular carcinoma and predicting prognosis, immune features, and drug sensitivity

Abstract

Background

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

Update Onkologie

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2024

Correction to: Efficacy and safety of trifluridine/tipiracil (TAS‑102) in patients with metastatic colorectal cancer: a systematic review and meta‑analysis

Proteomics-based clustering of lung adenocarcinoma identifies three subtypes with significantly different clinical and molecular features

LINC00844 suppresses tumor progression and predicts survival outcomes through inhibiting miR-19a-5p in cholangiocarcinoma

Correction to: Sensitivity analysis of EGFR L861Q mutation to six tyrosine kinase inhibitors

Efficacy and safety of trifluridine/tipiracil (TAS-102) in patients with metastatic colorectal cancer: a systematic review and meta-analysis

A gene signature of cancer-associated fibroblasts predicts prognosis and treatment response in bladder cancer

Neu im Fachgebiet Onkologie

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

Update Onkologie